BAKER BROS. ADVISORS LP, a director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), bought $29.26 million of company stock in transactions dated November 6th, 2026. The purchase covered 76,140 shares and was reported across three separate filings.
The buyer is an institution rather than an individual officer. Baker Bros. Advisors LP holds a board seat at Madrigal, which is why its trades in the stock surface in the insider record at all. That distinction matters when reading the size of the figure: a specialist healthcare investment firm moving nine figures of capital is doing something different from a chief financial officer writing a personal check.
Madrigal operates in the Pharmaceutical Preparations sector and carries a market capitalization of $10,049,107,968.
On position size, the buy is large in absolute dollars but needs to be set against the scale of the company. A firm with a director designation at a company of this size is typically already a substantial holder, so the shares added here sit on top of an existing stake rather than opening a new one.
The other side of the ledger is what the filings do not say. A Form 4 records the trade, the date, the share count and the price. It does not record intent, and nothing in the record explains the reasoning. Institutional buying by an affiliated fund can reflect portfolio mechanics as readily as a view on the business, and readers should weigh it accordingly.
On price, the three filings show executions between $383.015 and $396.61 per share. MDGL last traded at $432.60, which puts the current quote above the top of the range the firm paid. Anyone looking at the same trade today would be paying more than the insider did on November 6th, 2026.
Figures in this article come from Form 4 filings submitted to the Securities and Exchange Commission and from market data for MDGL.
Track every Form 4 filed at MADRIGAL PHARMACEUTICALS, INC. (MDGL) → insiderbuying.com/companies/MDGL